Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07575906 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.
A Phase 1 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07575906: Recruiting Phase 1 study, sponsored by Pfizer.
NCT07575906 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07575906, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who are healthy adults. Everyone who participates in this study will receive the study medicine. The study medicine may be given as a solution or as a tablet. Participants will be dosed once a week for 5 weeks. The investigator will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe. Participants will be involved in this study for up to 13 weeks from screening to follow-up visit. Participants stay in the study clinic for the 5 week dosing duration of the study, with two follow-up visits subsequently, either in person or by telephone call.
Primary Outcome
Assessment of TEAEs, SAEs, clinical laboratory values, vital signs, continuous cardiac monitoring and 12-lead ECGs
Interventions
- DRUG PF-08057418
- OTHER Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-05-08 |
| Est. Completion | 2026-07-23 |
| Phase | Phase 1 |
What NCT07575906 shows while recruiting
NCT07575906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which PF-08057418 is the first listed.
NCT07575906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07575906 about?
NCT07575906 is a clinical study titled "A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.". The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who...
What is the current status of trial NCT07575906?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-05-08. Estimated completion is 2026-07-23.
What interventions are being tested in trial NCT07575906?
The interventions under investigation include: PF-08057418 (DRUG), Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.) (OTHER).
Who is sponsoring clinical trial NCT07575906?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07575906's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI